Endophthalmitis: Sterile unit cefuroxime dose needed

Article

If a sterile unit dose of cefuroxime were available it would become the world standard for endophthalmitis prophylaxis following the startling proof of its efficacy in the ESCRS endophthalmitis study last year. That was the conclusion of a debate for and against intracameral antibiotics at the JCRS Symposium, Controversies in Cataract & Refractive Surgery.

Endophthalmitis: sterile unit cefuroxime dose needed

If a sterile unit dose of cefuroxime were available it would become the world standard for endophthalmitis prophylaxis following the startling proof of its efficacy in the ESCRS endophthalmitis study last year. That was the conclusion of a debate for and against intracameral antibiotics at the JCRS Symposium, Controversies in Cataract & Refractive Surgery.

"The risk of TASS from kitchen pharmacy, and the litigious nature of medical practice in the United States, means that cefuroxime is not the prophylaxis of choice there," said Randall Olson, of the John A. Moran Center in the US, speaking against intracameral injection.

Dr Olson pointed out that pre- and postoperative topical antibiotics provided good coverage, and he would like to see a study testing the efficacy of pre- and postoperative topical application of fourth-generation fluoroquinolones. He added that gram-positive resistance to cefuroxime is increasing.

Dr Barry rejoined that such a study would prove extremely expensive and would encounter ethical dilemmas given a proven, safe treatment already exists. "We're getting an incidence of just 0.05% of endophthalmitis cases with intracameral cefuroxime, showing the best proven prophylaxis for endophthalmitis. It is effective against the majority of the organism."

He added that there are also organisms resistant to fourth-generation fluoroquinolones such as the enterococci and staphylococcus aureus.

Dr Olson concluded that the two were largely in agreement. "If we had a sterile unit dose, intracameral cefuroxime would be the world standard prophylaxis."

New Acri.Tec monotoric bifocal lens takes to the stage

Continuing on the path of IOL innovation, Acri.Tec unveiled the latest offering from its family of lenses in the form of the monotoric bifocal Acri.LISA Toric 466 TD lens.

According to the company, the lens combines the strong, proven visual performance of the Acri.LISA bifocal lens in near, intermediate and distance vision with the reliable and stable astigmatic correction of the firm's Acri.Comfort bitoric lens.

The Acri.LISA Toric is monotoric with an aspheric toric front surface and an aspheric diffractive back surface with Acri.Tec's patented SMP technology. The lens can also be implanted through a 1.5 mm incision, and hence can be used to perform microincision cataract surgery.

Refractive surgery will disappear to be replaced by RLE

Dr Howard I. Fine told delegates that he was the best ophthalmic surgeon because none of his patients used glasses. He then showed the audience a video of 'patients', all wearing spectacles, drinking directly from bottles of wine. It was a lighted finish in keeping to the session's theme, "I am the best because. . .".

At the same time, Dr Fine did map out important and developing areas in refractive lens exchange (RLE), which he believes will mean that the procedure becomes the refractive intervention of choice.

"Cataract or lens extraction is incredibly safe and efficacious," he said. "It improves outcomes with lower energy, smaller incisions, adjunctive refractive techniques and increased accuracy and safety. It's evolved into a refractive surgery."

He noted there are limitations in LASIK, particularly for high hyperopes, high myopes and presbyopes and, and age-induced changes in the spherical aberration of patients' crystalline lens will mean further treatment will be necessary.

RLE, on the other hand, just keeps expanding, with many developing multifocal and accommodative options, like the Tecnis Multifocal (AMO), the Synchrony (Visiogen) and NuLens (NuLens) accommodative lenses, the Smart IOL (Medennium Inc.) and the Calhoun light adjustable lens (LAL) (Calhoun Vision). Other interesting technologies are just beginning to emerge, like the LiquiLens (Vision Solutions Technologies) or pixelate optics.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
Related Content
© 2025 MJH Life Sciences

All rights reserved.